Table 2.
Use of concomitant medications at first direct oral anticoagulant (DOAC) dispensation with significant temporal changes between 2014 and 2018, presented per DOAC
| Dabigatran | Rivaroxaban | Apixaban | Edoxaban | |||||
|---|---|---|---|---|---|---|---|---|
| 2014 (n = 4,324) | 2018 (n = 7,473) | 2014 (n = 3,103) | 2018 (n = 12,672) | 2014 (n = 866) | 2018 (n = 11,784) | 2014 (n = 0) | 2018 (n = 3,486) | |
| Number of interacting drugs | 1.27 ± 0.53 | 1.23 ± 0.51 | 1.26 ± 0.54 | 1.21 ± 0.50 | 1.24 ± 0.49 | 1.23 ± 0.51 | – | 1.28 ± 0.56 |
| Amiodarone | 12.8% (554) | 10.8% (1969) | 12.4% (385) | 8.9% (2,389) | 11.8% (102) | 9.9% (2,368) | – | 10.6% (591) |
| Digoxin | 42.9% (1,855) | 38.9% (7,083) | 39.3% (1,221) | 35.5% (9,547) | 43.2% (374) | 40.3% (9,598) | – | 37.1% (2,063) |
| Diltiazem | 4.9% (212) | 3.7% (683) | 4.8% (149) | 3.5% (937) | 3.9% (34) | 2.8% (655) | – | 4.0% (222) |
| Verapamil | 19.2% (829) | 14.0% (2557) | 22.7% (704) | 13.7% (3676) | 19.7% (171) | 12.6% (3,009) | – | 12.2% (677) |
| Atorvastatin | 29.8% (1,287) | 35.9% (6,534) | 28.9% (897) | 34.0% (9,125) | 28.1% (243) | 34.9% (8,307) | – | 32.8% (1,825) |
| Clarithromycin | 1.1% (47) | 1.8% (324) | 0.6% (18) | 1.2% (313) | 0.9% (8) | 1.2% (294) | – | 1.3% (75) |
| Protease inhibitors | 0.0% (1) | 0.0% (9) | 0.0% (0) | 0.0% (6) | 0.0% (0) | 0.0% (2) | – | 0.1% (4) |
| Fluconazole | 0.9% (37) | 1.1% (204) | 0.5% (16) | 1.3% (341) | 0.5% (4) | 1.3% (306) | – | 1.6% (90) |
| Antiepileptic drugs | 2.6% (114) | 3.6% (665) | 2.3% (70) | 3.9% (1,042) | 2.3% (20) | 3.8% (898) | – | 3.4% (188) |
| Antimitotic drugs | 0.0% (0) | 0.0% (3) | 0.0% (0) | 0.1% (19) | 0.0% (0) | 0.0% (9) | – | 0.1% (4) |
| Doxorubicin | 0.0% (0) | 0.0% (3) | 0.0% (0) | 0.1% (15) | 0.0% (0) | 0.0% (0) | – | 0.1% (3) |
| Tyrosine kinase inhibitors | 0.0% (0) | 0.2% (29) | 0.0% (0) | 0.2% (45) | 0.0% (0) | 0.1% (26) | – | 0.2% (13) |
| Antihormonal drugs | 0.7% (32) | 1.1% (197) | 1.0% (30) | 1.7% (462) | 0.3% (3) | 1.2% (276) | – | 2.1% (115) |
| Calcineurin inhibitors | 0.1% (3) | 0.1% (22) | 0.1% (2) | 0.8% (215) | 0.2% (2) | 1.0% (242) | – | 0.8% (47) |
| Dexamethasone | 0.9% (41) | 3.1% (566) | 1.0% (31) | 5.4% (1462) | 0.7% (6) | 3.8% (912) | – | 8.8% (491) |
| Sertraline | 0.9% (41) | 1.3% (240) | 1.3% (40) | 1.7% (455) | 0.3% (3) | 1.5% (348) | – | 1.5% (79) |
| Amitriptyline | 3.8% (163) | 4.6% (837) | 3.8% (118) | 5.9% (1,572) | 5.8 (50) | 5.0% (1,192) | – | 4.8% (266) |
| Haloperidol | 0.6% (25) | 1.6% (299) | 0.5% (16) | 1.5% (391) | 0.3% (3) | 1.7% (395) | – | 1.6% (87) |
| Methotrexate | 2.5% (108) | 3.2% (588) | 3.4% (105) | 3.9% (1,061) | 2.4% (21) | 3.5% (834) | – | 3.4% (187) |
Data are mean ± standard deviation and percentage (number).